Home AMGN
231.2836
  Price0.19%   +0.3436
 
loading
Oct-04-22 05:45AM Amgen (AMGN) Gains But Lags Market: What You Should KnowZacks Investment Research
Oct-03-22 05:56AM The Short List Of Dow Jones Stocks That Are Actually Up This Year: Hint — It's Very ShortBenzinga
10:45AM Could This Biosimilar Drug Candidate Be a Hit for Novartis?The Motley Fool
Oct-03-22 09:35AM Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales?Zacks Investment Research
09:12AM Will New Drugs Help Bristol Myers (BMY) Combat Generic Pressure?Zacks Investment Research
Oct-02-22 01:58AM Bristol-Myers Squibb: A Gem In A Period Of Macroeconomic UncertaintiesSeeking Alpha
Sep-28-22 08:00AM 3 Biotech Stocks to Buy and Hold for the Next 10 YearsThe Motley Fool
Sep-27-22 07:01AM Wall Street Breakfast: Dollar Vs. StocksSeeking Alpha
Sep-26-22 10:30AM Dow Jones ETF Avoids Bear Market: 4 Stocks in GreenZacks Investment Research
Sep-24-22 09:00AM The Near-Perfect Portfolio: Sleep Well During Turbulent TimesSeeking Alpha
Sep-22-22 11:30AM AstraZeneca's (AZN) Asthma Drug Tezepelumab Gets Nod in EuropeZacks Investment Research
Sep-20-22 11:12AM Novartis (NVS) Unit Posts Positive Results on Prolia BiosimilarZacks Investment Research
Sep-19-22 06:20AM Should You Invest in the VanEck Biotech ETF (BBH)?Zacks Investment Research
Sep-16-22 02:59AM Amgen's new cancer drug faces questions about competitionMarketWatch
08:26AM Amgen's new cancer drug faces questions about competitionMarketWatch
Sep-16-22 07:48AM Amgen's new cancer drug faces questions about competitionMarketWatch
Sep-15-22 01:03AM Amgen's new cancer drug faces questions about competitionMarketWatch
Sep-14-22 10:30AM 3 High-Yielding Dividend Stocks That May Hike Their Payouts in the Next 2 YearsThe Motley Fool
02:23AM Why The CPI Sent The Dow Down By Over 1,200 PointsSeeking Alpha
Sep-12-22 03:40AM Bristol Myers (BMY) Gets FDA Approval for Psoriasis CandidateZacks Investment Research
11:08AM Livent, Amgen And Some Other Big Stocks Moving Lower On MondayBenzinga
Sep-12-22 07:37AM 3 Stocks Expecting Good News From the FDAThe Motley Fool
06:20AM Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?Zacks Investment Research
Sep-09-22 05:45AM Amgen (AMGN) Gains But Lags Market: What You Should KnowZacks Investment Research
10:23AM Could This Biosimilar Drug Candidate Be a Winner for Amgen?The Motley Fool
Sep-09-22 07:57AM The Zacks Analyst Blog Highlights: T-Mobile US, NextEra Energy, Amgen, 3M and Itau Unibanco HoldingZacks Investment Research
Sep-08-22 06:20AM Should You Invest in the iShares Biotechnology ETF (IBB)?Zacks Investment Research
Sep-06-22 06:52AM Take the Zacks Approach to Beat the Market: Walmart (WMT), Ulta Beauty (ULTA), UniCredit (UNCFF) in FocusZacks Investment Research
Sep-05-22 09:22AM 3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement IncomeZacks Investment Research
08:00AM Is This Blue Chip Dividend Stock a Buy?The Motley Fool
Aug-31-22 12:12PM Amgen's (AMGN) Lumakras Meets Goal in New Lung Cancer StudyZacks Investment Research
11:32AM Aerie (AERI) Rallies 205.6% in the Past Three Months: Here's WhyZacks Investment Research
Aug-31-22 09:53AM What This News Might Mean for AmgenThe Motley Fool
Aug-30-22 11:22AM Amgen (AMGN) Outperforms Industry Year to Date: What's Next?Zacks Investment Research
Aug-29-22 05:56AM Why Dividend Stocks Could Soon Be More Attractive -- Thanks to Joe BidenThe Motley Fool
Aug-28-22 06:34AM U.S.-China relations just got a whole lot better, boosting the prospects of these three stocksMarketWatch
Aug-24-22 01:33AM Amgen (AMGN) Posts Positive Data from Soliris' Biosimilar StudyZacks Investment Research
09:45AM These 10 stocks matter the most to hedge funds right nowMarketWatch
Aug-24-22 08:40AM 2 Top Biotech Stocks to Buy for the Long HaulThe Motley Fool
Aug-19-22 05:44AM This Easy-to-Use Stock Strategy Is Crushing the MarketThe Motley Fool
Aug-18-22 08:00AM How Are Biotech ETFs Reacting to Q2 Earnings Releases?Zacks Investment Research
Aug-17-22 09:15AM Has Moderna Made a Bear Market Blunder?The Motley Fool
05:35AM The Zacks Analyst Blog Highlights Coca-Cola, Oracle, Morgan Stanley, Amgen and TotalEnergiesZacks Investment Research
Aug-16-22 01:23AM Retail Scorecard and Analyst Reports for Coca-Cola, Oracle & Morgan StanleyZacks Investment Research
09:40AM Amgen (AMGN) is a Top-Ranked Value Stock: Should You Buy?Zacks Investment Research
Aug-14-22 12:50PM Dividend Champion, Contender, And Challenger Highlights: Week Of August 14Seeking Alpha
Aug-12-22 06:05AM The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex PharmaceuticalsZacks Investment Research
Aug-11-22 11:25AM Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More UpdatesZacks Investment Research
07:30AM Get ready for more merger mania in the pharma sector for the rest of the yearMarketWatch
Aug-09-22 04:46AM Get ready for more merger mania in the pharma sector for the rest of the yearMarketWatch
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; The University of Texas MD Anderson Cancer Center, and Provention Bio, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Cap:    |  Volume (24h):